Your browser is no longer supported. Please, upgrade your browser.
MRNS Marinus Pharmaceuticals, Inc. weekly Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.97 Insider Own0.63% Shs Outstand24.94M Perf Week6.99%
Market Cap377.15M Forward P/E- EPS next Y-2.15 Insider Trans0.00% Shs Float20.73M Perf Month65.59%
Income-72.40M PEG- EPS next Q-0.63 Inst Own77.80% Short Float17.85% Perf Quarter20.32%
Sales- P/S- EPS this Y-10.60% Inst Trans43.11% Short Ratio2.86 Perf Half Y85.69%
Book/sh3.70 P/B3.47 EPS next Y23.20% ROA-84.60% Target Price- Perf Year131.12%
Cash/sh3.61 P/C3.56 EPS next 5Y20.00% ROE-126.50% 52W Range4.04 - 16.28 Perf YTD48.73%
Dividend- P/FCF- EPS past 5Y14.50% ROI- 52W High-21.07% Beta1.50
Dividend %- Quick Ratio11.50 Sales past 5Y- Gross Margin- 52W Low218.07% ATR1.30
Employees42 Current Ratio11.50 Sales Q/Q- Oper. Margin- RSI (14)66.78 Volatility11.21% 11.28%
OptionableYes Debt/Eq0.00 EPS Q/Q33.60% Profit Margin- Rel Volume0.79 Prev Close11.62
ShortableYes LT Debt/Eq0.00 EarningsAug 06 BMO Payout- Avg Volume1.29M Price12.85
Recom1.40 SMA2026.73% SMA5051.75% SMA20046.73% Volume1,014,235 Change10.59%
Sep-30-20Initiated Truist Buy $35
Jul-01-20Reiterated H.C. Wainwright Buy $6 → $9
Jul-01-20Initiated Cowen Outperform
Apr-09-20Initiated Craig Hallum Buy $4.50
Dec-20-19Initiated Oppenheimer Outperform
Mar-05-19Resumed Jefferies Buy $3.50 → $10
Feb-27-19Downgrade Mizuho Buy → Neutral $13 → $5
Feb-06-19Initiated Leerink Partners Outperform $10
Jul-02-18Initiated Cantor Fitzgerald Overweight $19
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
Sep-25-20 07:37AM  
Sep-24-20 04:01PM  
Sep-22-20 09:14AM  
Sep-16-20 08:00AM  
Sep-15-20 07:09PM  
11:38AM  
10:38AM  
10:33AM  
09:55AM  
07:55AM  
Sep-14-20 04:01PM  
08:00AM  
Sep-08-20 04:01PM  
Aug-27-20 03:30PM  
Aug-25-20 08:52AM  
Aug-11-20 08:04PM  
Aug-06-20 07:30AM  
Aug-04-20 12:13PM  
Jul-30-20 10:52AM  
07:30AM  
Jul-29-20 04:00PM  
Jul-08-20 09:19PM  
Jun-30-20 07:00AM  
Jun-24-20 08:00AM  
Jun-22-20 10:16AM  
Jun-17-20 08:44AM  
Jun-16-20 06:39PM  
Jun-15-20 07:30AM  
Jun-02-20 04:01PM  
May-28-20 09:23PM  
04:01PM  
May-14-20 02:22PM  
May-09-20 07:51AM  
May-04-20 07:30AM  
May-03-20 08:45AM  
Apr-30-20 07:30AM  
Apr-27-20 04:01PM  
Apr-23-20 07:30AM  
Apr-14-20 09:28PM  
Mar-23-20 04:38PM  
Mar-20-20 10:21AM  
Mar-19-20 07:30AM  
Mar-18-20 08:19AM  
Mar-16-20 07:30AM  
Feb-25-20 07:30AM  
Feb-24-20 07:30AM  
Feb-14-20 04:05PM  
Feb-03-20 07:30AM  
Jan-20-20 04:37AM  
Jan-13-20 07:30AM  
Jan-07-20 07:30AM  
Dec-26-19 09:00AM  
Dec-24-19 11:29AM  
Dec-23-19 08:30AM  
Dec-13-19 04:44PM  
04:01PM  
Dec-12-19 07:30AM  
Dec-11-19 12:09PM  
10:31AM  
09:00AM  
07:21AM  
Dec-10-19 04:25PM  
Dec-09-19 06:30AM  
Dec-07-19 12:01AM  
Nov-27-19 07:30AM  
Nov-08-19 04:00PM  
Nov-06-19 07:30AM  
Oct-29-19 07:30AM  
Oct-17-19 07:30AM  
Oct-16-19 07:06AM  
Oct-13-19 04:33PM  
Sep-27-19 04:05PM  
03:08PM  
Sep-26-19 04:32PM  
11:16AM  
07:30AM  
Sep-25-19 11:36AM  
Sep-20-19 09:36AM  
Aug-23-19 04:06PM  
09:19AM  
Aug-09-19 12:00PM  
Aug-08-19 07:30AM  
Jul-23-19 01:53PM  
11:30AM  
07:30AM  
Jun-29-19 07:18PM  
Jun-27-19 12:46PM  
Jun-20-19 11:22AM  
Jun-19-19 04:00PM  
Jun-03-19 07:30AM  
May-27-19 09:22AM  
May-01-19 07:53AM  
07:30AM  
Apr-26-19 01:19PM  
Mar-19-19 08:46AM  
Mar-11-19 09:57AM  
09:55AM  
07:30AM  
Mar-06-19 07:30AM  
Mar-05-19 02:51PM  
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Edward FCFOJan 30Sale2.052,3804,87917,717Feb 03 06:29 PM
Braunstein ScottChief Executive OfficerDec 13Buy1.25100,000125,000100,000Dec 13 04:08 PM